Viking Therapeutics (VKTX) Cash from Financing Activities (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Cash from Financing Activities data on file, last reported at $12.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 3360.46% year-over-year to $12.1 million; the trailing twelve-month figure through Mar 2026 stood at $88.2 million (up 1201.17% YoY), and the FY2025 full-year result was $76.4 million, down 87.52% from the prior year.
• Cash from Financing Activities declined to $12.1 million in Q1 2026, from $75.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $606.0 million in Q1 2024 to a low of -$5.0 million in Q1 2022.
• A 5-year average of $57.4 million and a median of $1.0 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 22770.21% in 2022 and slumped 840.0% in 2023, its largest moves.
• Tracing VKTX's Cash from Financing Activities over 5 years: stood at $10.7 million in 2022, then slumped by 98.25% to $188000.0 in 2023, then surged by 431.91% to $1.0 million in 2024, then jumped by 7410.3% to $75.1 million in 2025, then slumped by 83.92% to $12.1 million in 2026.
• Business Quant data shows VKTX's Cash from Financing Activities at $12.1 million in Q1 2026, $75.1 million in Q4 2025, and $480000.0 in Q3 2025.